Enerpac Tool Group Reports Fourth Quarter and Full-Year Fiscal 2026 Results; Introduces Fiscal 2027 Outlook

Enerpac posts strong sales and cash flow, but net earnings dip on higher costs.

What the company is saying

Enerpac Tool Group Corp. reports fourth quarter net sales of $185.7 million and full-year sales of $652.3 million, emphasizing broad-based product strength across the Americas and robust cash generation. President and CEO Paul Sternlieb highlights the completion of the SFE Group acquisition and asserts the company’s financial flexibility to continue its capital allocation strategy. Darren Kozik, Executive Vice President and CFO, frames the fiscal 2027 guidance as building on healthy business trends and incorporating ten months of SFE Group results. The company explains the year-over-year net earnings decline as driven by product mix, higher incentive compensation, and investments for future growth. Guidance for fiscal 2027 includes net sales of $825–$845 million, organic sales growth of 4–6%, adjusted EBITDA of $195–$205 million, and adjusted diluted EPS of $2.00–$2.15. The narrative is confident, with management pointing to strong balance sheet metrics and ongoing investments in commercial excellence, innovation, and productivity.

What the data suggests

Net sales increased to $185.7 million in the fourth quarter, up from $167.5 million, and full-year sales rose to $652.3 million from $616.9 million. Gross profit margin for the year was 49.2%, down from 50.5%, and net earnings declined to $89.7 million from $92.7 million. Diluted EPS for the year edged up to $1.72 from $1.70, while adjusted diluted EPS improved to $1.87 from $1.81. Adjusted EBITDA for the year was $154.3 million, nearly flat versus $153.6 million in the prior year. Free cash flow rose sharply to $119.6 million from $92.0 million, and cash provided by operating activities increased to $130.2 million from $111.3 million. The cash balance at year-end was $174.7 million, with net debt at just $7.6 million and net debt to adjusted EBITDA at 0.1x, indicating a strong liquidity position. Organic sales growth was 10% in the fourth quarter and 4% for the year, with Cortland Biomedical organic sales up 23% for the year. The company attributes the net earnings decline to mix, higher incentive compensation, and growth investments, but the overall financial trajectory is positive in sales and cash flow. Fiscal 2027 guidance projects further growth, with net sales targeted at $825–$845 million and adjusted EBITDA at $195–$205 million.

Analysis

The announcement provides a detailed and balanced disclosure of Enerpac Tool Group Corp.'s fiscal 2026 results, including realised figures for net sales, earnings, margins, cash flow, and segment performance. The tone is positive, highlighting organic growth, robust cash generation, and the completion of the SFE Group acquisition. Forward-looking statements are limited to fiscal 2027 guidance, which is standard for a year-end release and is supported by the inclusion of recent acquisition results. There is no evidence of exaggerated claims or narrative inflation; most statements are factual and supported by disclosed metrics. The only minor inflation is in qualitative assertions about 'financial flexibility' and 'disciplined capital allocation,' which are not directly quantified but are not materially misleading given the strong balance sheet data. No large capital outlay is paired with only long-dated, uncertain returns, and the guidance period is near-term (next fiscal year).

Risk flags

• ●Margin pressure is evident, as gross profit margin declined from 50.5% to 49.2% year-over-year and adjusted EBITDA margin fell from 24.9% to 23.7%. This suggests cost or pricing challenges that could persist if not addressed.
• ●Net earnings declined to $89.7 million from $92.7 million, with management citing higher incentive compensation and investments for growth. If these costs do not translate into future revenue or margin expansion, profitability could remain under pressure.
• ●Fiscal 2027 guidance assumes no substantial change to the current tariff or regulatory environment and stable foreign exchange rates. Any adverse shifts in these external factors could impact the company’s ability to meet its targets.
• ●The integration of SFE Group, completed during the year, presents execution risk. Failure to realize anticipated synergies or operational disruptions could affect both short-term and long-term results.

Bottom line

Enerpac delivered solid top-line and cash flow growth in fiscal 2026, with net sales up to $652.3 million and free cash flow rising to $119.6 million. Despite these gains, net earnings fell to $89.7 million, reflecting higher costs and investments that have yet to yield margin expansion. The company’s balance sheet is robust, with net debt at just $7.6 million and strong liquidity. Fiscal 2027 guidance is ambitious, targeting up to $845 million in sales and $205 million in adjusted EBITDA, but achieving these goals depends on stable macro conditions and successful integration of SFE Group. Investors should watch for margin trends and evidence that growth investments are translating into improved profitability. The key takeaway is that while sales momentum and cash generation are strong, margin recovery and cost discipline will be critical to sustaining earnings growth.

Announcement summary

(NYSE:EPAC) Enerpac Tool Group Corp. reported its financial results for the fourth quarter and full fiscal year ended August 31, 2026. Net sales for the fourth quarter were $185.7 million, up from $167.5 million in the prior year period, and full-year net sales were $652.3 million, compared to $616.9 million in fiscal 2025. Gross profit margin for the fourth quarter was 47.0%, and for the full year was 49.2%. Net earnings for the fourth quarter were $24.4 million, down from $28.1 million, and for the full year were $89.7 million, compared to $92.7 million in the prior year. Diluted earnings per share (EPS) for the fourth quarter was $0.47, and for the full year was $1.72, up from $1.70 in fiscal 2025. Adjusted diluted EPS was $0.53 for the quarter and $1.87 for the year, compared to $0.52 and $1.81, respectively, in the prior year. Adjusted EBITDA for the fourth quarter was $42.1 million and $154.3 million for the full year, versus $44.5 million and $153.6 million in fiscal 2025. Free cash flow for fiscal 2026 was $119.6 million, up from $92.0 million in fiscal 2025. Cash provided by operating activities was $130.2 million, compared to $111.3 million in the prior year. The cash balance as of August 31, 2026, was $174.7 million, with a debt balance of $182.3 million and net debt of $7.6 million. Net debt to adjusted EBITDA was 0.1x at year-end. Restructuring and M&A charges were $0.15 per diluted share in fiscal 2026, compared to $0.11 in fiscal 2025. Organic sales increased 10% in the fourth quarter and 4% for the full year. The Industrial Tools & Services (IT&S) segment saw organic sales up 10% in the quarter and 3% for the year, while Cortland Biomedical organic sales rose 13% in the quarter and 23% for the year. The company completed the SFE Group acquisition during the year. For fiscal 2027, Enerpac issued guidance of net sales between $825 million and $845 million, organic sales growth of 4% to 6%, adjusted EBITDA between $195 million and $205 million, and adjusted diluted EPS between $2.00 and $2.15. The fiscal 2027 guidance includes approximately 10 months of SFE Group results. The company will host an investor conference call on October 29, 2026, and an Investor Day at the New York Stock Exchange on November 4, 2026. The company noted that its guidance is based on key foreign exchange rate assumptions and assumes no substantial change to the current tariff or regulatory environment. The company highlighted broad-based product strength across the Americas, encouraging trends in its service business, and robust cash generation. Net earnings declined year-over-year due to mix, higher incentive compensation, and investments for future growth. The company stated it has the financial flexibility to continue executing its disciplined capital allocation strategy.

Disagree with this article?